flavin-mononucleotide and Asthenia

To analyze the efficacy of cytoflavin in the complex treatment of sleep disorders in asthenic syndrome.. One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied. The patients were divided into three groups depending on the type of therapy: the first group received intravenous infusions of cytoflavin for 10 days; the second group, in addition to cytoflavin, received per os melatonin (3 mg or 5 mg) at bedtime; the third group in addition to cytoflavin received per os zopiclone (7.5 mg) at bedtime.. On the 14th day of the study, a decrease in severity or complete relief of asthenia manifestations (according to the SHAS scale) and, accordingly, improvement or normalization of sleep in 97% of patients was found. At the same time, during polysomnographic study, the data obtained are characteristic for improving the quality of sleep phases mainly in the first and second groups of patients and, to a lesser extent, in the third group.. Cytoflavin effectively suppresses the main manifestations of asthenic syndrome, including sleep disorders.. Цель исследования. Анализ эффективности применения лекарственного препарата (ЛП) Цитофлавин в комплексной коррекции расстройств сна при астеническом синдроме (АС). Материал и методы. Обследовали 100 пациентов с расстройствами сна на фоне АС различной этиологии и степени выраженности. Они были разделены на три группы в зависимости от вида проводимой терапии: 1-й группе больных были назначены внутривенные инфузии ЛП Цитофлавин в течение 10 дней; 2-й группе в дополнение к ЛП Цитофлавин перед сном был назначен per os ЛП Мелатонин (3 или 5 мг); пациенты 3-й группы в дополнение к ЛП Цитофлавин получали перед сном per os ЛП Зопиклон (7,5 мг). Результаты и заключение. На 11-й день исследования было выявлено уменьшение выраженности или полное купирование проявлений астении (по шкале ШАС) и соответственно улучшение или нормализация сна у 97% больных. Вместе с тем при полисомнографическом исследовании получены данные, характерные для улучшения качества фаз сна, преимущественно в 1-й и 2-й группах пациентов и в меньшей степени в 3-й группе. Цитофлавин, являясь нейрометаболическим энергокорректором с антигипоксической и антиоксидантной активностью, эффективно купирует основные проявления АС, в том числе при нарушениях сна.

Topics: Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Melatonin; Niacinamide; Sleep Wake Disorders; Succinates; Syndrome; Treatment Outcome

The present observational study addressed effects of cytoflavine on symptoms of asthenia and emotional and autonomic regulation in patients with organic emotional-labile (asthenic) disorder (F06.6). Fifty one females and 49 males (mean age 36.8±11.0 years) were included into the study during their in-patient treatment in Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department. All patients received standard antidepressant and vascular therapy, were consulted by psychologists or psychotherapists, visited physiotherapeutic procedures, massage and medical physical training. In addition, 50 patients received cytoflavin two tablets twice per day. At the psychiatric re-assessment before discharge both cytoflavin and control groups showed similar significant reduction of asthenia symptoms. At the same time, patients with cognitive deficits showed significantly larger improvement of cognitive functions after cytoflavin treatment in comparison with cognitively deficient patients after only standard therapy. Improvement of depressive symptoms was significantly larger in cytoflavin group in comparison with controls as well. These data are consistent with previous studies which showed cytoflavin to be effective as a treatment for patients with cognitive deficits and organic depression.

Topics: Adult; Asthenia; Autonomic Nervous System; Drug Combinations; Emotions; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Succinates; Treatment Outcome

The author presents results of multicentre randomized studies of therapeutic efficiency of cytoflavin tablets in patients with chronic cerebral ischemia including asthenovegetative syndrome. Cytoflavin was shown to reduce clinical manifestations of asthenia, anxiety, depression, cognitive and emotional disorders and simultaneously improve quality of life. The efficiency of cytoflavin is confirmed by improved physical and psychic state of the patients, their enhanced social activity.

Topics: Asthenia; Brain Ischemia; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Multicenter Studies as Topic; Neuropsychological Tests; Niacinamide; Quality of Life; Randomized Controlled Trials as Topic; Succinates